Raising guidance? In this uncertainty?
Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
22 Apr 2025 Date | | - Cons. EPS | - EPS |
29 Jan 2025 Date | | 0.66 Cons. EPS | 0.7 EPS |
24 Oct 2024 Date | | 0.59 Cons. EPS | - EPS |
23 Oct 2024 Date | | 0.59 Cons. EPS | 0.63 EPS |
25 Jul 2024 Date | | 0.58 Cons. EPS | - EPS |
22 Apr 2025 Date | | - Cons. EPS | - EPS |
29 Jan 2025 Date | | 0.66 Cons. EPS | 0.7 EPS |
24 Oct 2024 Date | | 0.59 Cons. EPS | - EPS |
23 Oct 2024 Date | | 0.59 Cons. EPS | 0.63 EPS |
25 Jul 2024 Date | | 0.58 Cons. EPS | - EPS |
Medical Devices Industry | Healthcare Sector | Mr. Michael F. Mahoney CEO | NYSE Exchange | 101137107 Cusip |
Germany Country | - Employees | - Last Dividend | 6 Nov 2003 Last Split | 18 May 1992 IPO Date |
Boston Scientific Corporation is a global developer, manufacturer, and marketer of medical devices used in a variety of interventional medical specialties. Having begun its operations in 1979, the company has grown to serve a diverse range of medical needs through its two primary segments: MedSurg and Cardiovascular. With its headquarters in Marlborough, Massachusetts, Boston Scientific is committed to improving patient health by providing cutting-edge solutions that address complex medical conditions and enhance the quality of life for patients worldwide.